Clearance of p16-positive senescent cells not only increases ATP levels but also normalizes the expression of key enzymes in glycolysis, including hexokinase, lactate dehydrogenase, and pyruvate kinase in DKD kidneys, suggesting that an improvement of energy and glucose metabolism is a critical benefit of clearing p16-positive senescent cell therapy in DKD. This evidence concerns the gene CDKN2A and diabetic kidney disease.